Abstract
Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia
Highlights
Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia
A single dose of rFVIIa 180 lg kg)1 stopped mild-to-moderate bleeding in 59% of bleeding episodes in children
Haemostasis was achieved after a second dose of 90 lg kg)1 rFVIIa in a further 37% of bleeding episodes
Summary
Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia Recombinant activated factor VII (rFVIIa; NovoSevenÒ, Novo Nordisk, Bagsværd, Denmark) is considered the first-line treatment option for controlling bleeding in haemophilia patients with inhibitors [2].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call